Background: Renal denervation (RDN) through catheter ablation is emerging as a promising therapeutic option for refractory hypertension, but the decrease in blood pressure (BP) is difficult to predict and is usually evident only after months. No acute variable is available to date to predict the BP response. Methods: This analysis is based on 23 patients with RDN performed at our institution within the last 14 months. Complete information regarding all ablation points was present for 18 patients (194 ablation points). 15 patients had complete 3-months follow-up including 24-hour BP, and for 10 of these patients the complete information regarding the ablation points was present. Results: 20 patients had a bilateral RDN with 4,5Ϯ1,2 ablation points per renal artery, 2 patients only monolateral due to 40% narrowing of the other artery. One patients experienced asystoly after ostial RDN of the first renal artery requiring CPR and intubation. He received a pacemaker and recovered completely. 79,9% of ablation points required the max. energy output (8W). The BP decreased from 151/77 to 134/72 mmHg (Pϭ0.07 for syst. RR) and the percentage of patients with systolic BP Ͼ140mmHg from 57% to 31% (Pϭ0,04) on an average of 3,8Ϯ0,9 medications.
Background: Catheter-based intravascular renal denervation (RD) using radiofrequency energy has shown promise in the treatment of resistant hypertension. However, to date, no studies have examined the extent of renal nerve injury following RD. Methods: To examine renal nerve injury following RD, nine obese, hypertensive dogs underwent bilateral RD using the St. Jude Medical EnligHTN™ renal denervation system and eight weeks of hemodynamic monitoring. At the end of the eight-week period, both left and right renal arteries were collected from the aorta to the kidneys. The renal arteries were cut into equal sections, fixed, and embedded in paraffin. Multiple five-micron sections were taken from the bifurcation, main renal artery, and the ostium and stained with hematoxylin-eosin. Sections were examined for the total number of nerves, number of injured nerves, and the distance measured from nerves to the renal artery lumen. Results: Renal nerves were found from 0.28 mm to 6.7 mm from the renal artery lumen. Twelve percent of the nerves were found between 0.28mm and 1mm from the artery lumen, fifty-seven percent between 1mm and 2.5 mm, seventeen percent between 2.5mm and 3.5mm, and fourteen percent between 3.5mm and 6.7mm. Forty-two percent of nerves exhibited injury due to RD (157 out of 371); however, since samples were examined 8 weeks after RD, some injured nerves may have degenerated and become unobservable. Injury was found at nearly all distances from the artery lumen but was most prevalent from 0.28mm to 3.5mm. Renal nerve injury was found in thirty-six percent of the nerves near the bifurcation, forty-one percent in the main renal artery, and fifty-six percent near the ostium. Conclusions: Our data show that renal nerves span a great distance from the renal artery lumen in obese canines. These data also suggest that the RD travels approximately 3.5mm from the artery lumen surface in obese dogs; however, renal nerve injury is noted further out. The injury further from the luminal surface is presumably the result of Wallerian-type degeneration. The current study showed that RD using the St. Jude Medical EnligHTN™ renal denervation system does cause significant injury to renal nerves.
TCT-206 A Pilot Study on Renal Sympathetic Denervation for Resistant Hypertension in the West of Ireland

Imtiaz Kalyar 1 , James Gleeson 1 , Sajjad Matiullah 1 , Faisal Sharif 1 1 Galway University Hospitals, Galway, Galway
Background: Renal Sympathetic Denervation (RSD) is a novel, device-based intervention for the management of resistant essential hypertension (RH). Here we present the data from our initial experience of renal artery denervation for the first 12 patients. Methods: All patients in this pilot study (nϭ12) had RH, and were on a minimum of 3 medications. The effect of RSD on office blood pressure, 24 hour ambulatory blood pressure, number of anti-hypertensive medications, renal function, weight, serum uric acid concentration, excretory fraction of sodium, and renin-aldosterone levels was investigated. We also assessed the safety of the procedure. Prior to intervention secondary causes of hypertension were excluded, and detailed anatomy of the renal arteries was obtained using either CT or MR angiography. Patients were followed up at 2 weeks, 2 months and 6 months for serum biochemistry, urinalysis and office BP. Ambulatory BP was assessed pre-and 2 months post RSD. Results: At 2 months the average decrease in office BP was 33/15mmHg (systolic p ϭ 0.04, diastolic pϭ0.03), while the observed reduction in 24 hour ambulatory BP readings was 26/16mmHg (systolic pϭ0.01, diastolic pϭ0.01). The range in change of serum creatinine values at 2 months was Ϫ10 to ϩ13 mol/L, and the average change was ϩ1.5 mol/L (pϭ0.47). There was a 6.6% reduction in mean uric acid concentration (pϭ0.371). A trend towards weight loss, with an average reduction in weight of 1.65kg at 2 month follow up was seen (pϭ 0.27). Patients required, on average, 1.3 medications less at follow up. There have been no major complications to date. Conclusions: RSD was safe, and effective at reducing both systolic and diastolic blood pressure in patients with RH. No acute deterioration in renal function was demonstrated. Findings from this pilot study showed more substantial reductions in ambulatory BP consistent with larger studies. Background: Sympathetic renal denervation shows promise in treating resistant hypertension. The percutaneous RF ablation approach is currently undergoing evaluation but has several limitations. Vascular brachytherapy has the potential to damage nerves. The purpose of the present study was to assess safety and feasibility of renal artery brachytherapy for sympathetic renal denervation. Methods: A total of 10 normotensive domestic swine underwent vascular brachytherapy to left and right renal arteries using the Beta-Cath™ 3.5F System with doses of 25 Gy and 50 Gy at 2 mm from the source center. Each treated group had 8 arteries; 4 untreated arteries served as control. Follow-up obtained at 1 or 2 months included angiogram, intravascular ultrasound, norepinephrine levels and histopathology. Results: Overall the vascular brachytherapy procedure was safe and there were no apparent angiographic or ultrasound injuries to the vessel. Histology demonstrated a variable degree of thermal injury more pronounced in the 50 Gy group. The majority of the examined nerves showed some degree of injury. (Figure) There was a dose-related effect on the severity of the nerve injury. There was a varied degree of arteriolar changes in the examined sections; most showed a varied degree of endothelial cell loss of approximately 2% to 20%. 
TCT-207
Beta Radiation For Renal Nerve Denervation: Initial Feasibility And Safety
P O S T E R S
Conclusions: This initial feasibility and safety study of renal nerve denervation mediated by low and intermediate ␤-radiation dosages indicates that this approach can cause substatntial nerve damage while avoiding significant damage to the renal artery.
TCT-208
Catheter-based renal sympathetic denervation -results of the heidelberg registry 
University of Heidelberg, Heidelberg, Germany
Background: Renal sympathetic denervation is a novel treatment option in patients with treatment resistant hypertension. Registry data allow to evaluate safety and efficacy in a real-world szenario. Methods: 53 consecutive patients with treatment resistant hypertension underwent renal sympathetic denervation with the Symplicity radiofrequency based catheter. At baseline, mean office blood pressure was 171Ϯ22/93Ϯ17 mm Hg. The mean number of antihypertensive agents was 5.0. Results: At 6 months follow up, office systolic blood pressure improved to 151Ϯ18 mm Hg (minus 20 mm Hg compared to baseline; pϽ0.0001), the diastolic blood pressure to 86Ϯ11 mm Hg (minus 7 mm Hg compared to baseline, pϽ0.001). The response rate, defined as reduction of office systolic blood pressure of Ͼ10 mm Hg was 66%. In 9 Patients (17%), number of dosage of antihypertensive agents could be reduced. The mean number of ablations points per kidney was 4.3. There was no correlation between the number of ablation points and blood pressure response (rϭ 0,25, pϭns).
Conclusions:
Renal sympathetic denervation with the Simplicity systems results in a significant reduction of office systolic and diastolic blood pressure reduction in patients with treatment resistant hypertension. Effects on blood pressure were somewhat less profound than reported in the Symplicity trial program, reflecting a real world szenario with more liberal use of the method. Interestingly, there was no correlation between the number of ablation points and blood pressure response.
TCT-209
Durable Reduction In Blood Pressure In the First Cohort of Patients Treated With Renal Sympathetic Denervation Therapy For Resistant Hypertension
Sonny Palmer 1 , Michael Stokes 1 , Christopher Judkins 1 , Paul Williams 1 , Robert Whitbourn 1 1 St Vincent's Hospital, Melbourne, Victoria, Australia
Background: Resistant hypertension is associated with significant cardiovascular morbidity and mortality and it poses a significant treatment challenge for physicians. The treatment of resistant hypertension by renal sympathetic denervation (RD) has demonstrated excellent short-term reductions in blood pressure (BP) at six-months as reported by the Symplicity HTN-2 Investigators. The future role of RD is evolving and long-term results will clarify it's durability. Here we assess the long-term results in the first cohort of patients to be treated with RD in Australia.
Methods:
We compared the baseline office-based BP to long-term follow-up office-based BP, number of prescribed anti-hypertensive medications, major adverse cardiac and cerebrovascular events (MACCE) and hospital admissions in 8 patients whom had undergone RD from July 2007 to January 2008. Results: Our cohort had a mean follow-up of 43 months and we found that office-based BP measurements were reduced by a mean of 30/9 mmHg when compared to baseline measurements (pϽ0.003 systolic; pϽ0.09 diastolic). The mean number of prescribed anti-hypertensive medications remained stable throughout the follow-up period (4.88 medications pre-treatment vs 4.1 medications at follow-up; pϭNS). Two patients required hospitalisation for late cerebrovascular events. There were no cardiac events reported. Conclusions: This is the longest reported follow-up of renal sympathetic denervation patients. We have demonstrated a significant and durable decrease in blood pressure. However, there has been no reduction in the number of prescribed anti-hypertensive medications.
TCT-210
Decrease of the norepinephrine release from sympathetic nerves during renal denervation We assessed 11 patients with bilateral renal denervation for the changes of preand postprocedural norepinephrine (NE) and epinephrine (E) levels measured directly from the renal artery (RA) and vein (RV). We defined the respective spillover for ⌬NE and ⌬E as the difference RV-RA and compared this difference before and after the procedure.
Results:
We assessed NE and E for 88 probes (11 patients x 2 (bilateral probes) x 2 (RA and RV) x 2(pre-and post-procedural)). There was a significant decrease of the ⌬NE RV-RA spill-over comparing pre-with post-procedural levels (184pg/mlϮ180 decrease to 97pg/mlϮ137, Pϭ0.03 for paired t-test). There was no significant change in the epinephrine levels during the procedure under conscious sedation (56pg/mlϮ192 compared to 29pg/mlϮ171, Pϭ0.62 for paired t-test). The pre-post ⌬NE RV-RA was even more pronounced when the median values were compared (P ϭ 0.02).
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